EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring

Cecile Riviere-Cazaux iD, Yuta Suzuki, Zain Kizilbash, William J Laxen, Jean M Lacey, Tamara M Wipplinger, Arthur E Warrington, Michael B Keough, Lionel Fotso Kamga, Katherine M Andersen, Nicholas Canaday, Matthew L Kosel und 8 weitere

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 09.03.2026. Verfasst von Cecile Riviere-Cazaux und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Mayo Clinic, Rochester. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Imaging-based glioma monitoring is confounded by treatment-related changes. D-2-hydroxyglutarate (D-2-HG), produced by the isocitrate dehydrogenase (IDH) mutation, is detectable in cerebrospinal fluid (CSF), which can be sampled from cranial or lumbar compartments. We evaluated CSF D-2-HG as a serially accessible biomarker for IDH-mutant gliomas, including the optimal compartment for longitudinal sampling.

Methods

Lumbar and cranial CSF samples were collected from patients with IDH-mutant gliomas or IDH-wild-type central nervous system pathologies via surgical field collection, lumbar punctures, and CSF access devices. CSF D-2-HG was quantified via our CLIA-certified gas chromatography mass spectrometry assay.

Results

D-2-HG was significantly higher in cranial than lumbar CSF from IDH-mutant glioma patients. Consistent with low D-2-HG abundance in lumbar CSF, lumbar samples could not discriminate IDH-mutant gliomas from IDH-wild-type lesions. In contrast, cranial CSF D-2-HG was significantly higher in IDH-mutant gliomas than wild-type lesions, providing an adequate baseline for initial evaluations of monitoring capabilities. Across 75 samples from 7 consecutive patients with grade 4 IDH-mutant astrocytomas, serial cranial CSF D-2-HG decreased with cytoreduction, remained unchanged with stable disease, and increased with disease progression, but not pseudoprogression.

Conclusions

Serial cranial CSF D-2-HG shows promise as a monitoring biomarker for IDH-mutant gliomas.

Schlagwörter

Stichwörter der Autor:innen

2-hydroxyglutarateIDHbiomarkercerebrospinal fluidglioma

Autor:innen und Institutionen

  • Department of Neurological Surgery, Mayo Clinic, Rochester.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester.
  • Department of Neurology, Mayo Clinic, Rochester.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester.
  • Department of Medical Oncology, Mayo Clinic, Rochester.
  • Department of Radiology, Mayo Clinic, Rochester.

ORCID-Profile: Cecile Riviere-Cazaux, Paul A Decker, Jeanette E Eckel-Passow, Timothy J Kaufmann, Terry C Burns

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • NCATS NIH HHS
  • National Institute of Health
  • NINDS
  • Mayo Clinic Center for Individualized Medicine
  • Lucius & Terrie McKelvey

Zitieren

APA

Riviere-Cazaux, C., Suzuki, Y., Kizilbash, Z., Laxen, W. J., Lacey, J. M., Wipplinger, T. M., Warrington, A. E., Keough, M. B., Kamga, L. F., Andersen, K. M., Canaday, N., Kosel, M. L., Tortorelli, S., Sener, U., Ruff, M. W., Decker, P. A., Eckel-Passow, J. E., Kizilbash, S. H., Kaufmann, T. J., & Burns, T. C. (2026). Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag012

Vancouver

Riviere-Cazaux C, Suzuki Y, Kizilbash Z, Laxen WJ, Lacey JM, Wipplinger TM, et al. Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag012

BibTeX
@article{RiviereCazaux2026,
  author = {Riviere-Cazaux, Cecile and Suzuki, Yuta and Kizilbash, Zain and Laxen, William J and Lacey, Jean M and Wipplinger, Tamara M and Warrington, Arthur E and Keough, Michael B and Kamga, Lionel Fotso and Andersen, Katherine M and Canaday, Nicholas and Kosel, Matthew L and Tortorelli, Silvia and Sener, Ugur and Ruff, Michael W and Decker, Paul A and Eckel-Passow, Jeanette E and Kizilbash, Sani H and Kaufmann, Timothy J and Burns, Terry C},
  title = {Cerebrospinal fluid D-2-hydroxyglutarate for IDH-mutant glioma monitoring},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag012}
}
Kostenlos starten →